Unknown

Dataset Information

0

Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors.


ABSTRACT: Focused ultrasound (FUS) in the presence of microbubbles can transiently open the blood-brain barrier (BBB) to increase therapeutic agent penetration at the targeted brain site to benefit recurrent glioblastoma (rGBM) treatment. This study is a dose-escalating pilot trial using a device combining neuronavigation and a manually operated frameless FUS system to treat rGBM patients. The safety and feasibility were established, while a dose-dependent BBB-opening effect was observed, which reverted to baseline within 24 hours after treatment. No immunological response was observed clinically under the applied FUS level in humans; however, selecting a higher level in animals resulted in prolonged immunostimulation, as confirmed preclinically by the recruitment of lymphocytes into the tumor microenvironment (TME) in a rat glioma model. Our findings provide preliminary evidence of FUS-induced immune modulation as an additional therapeutic benefit by converting the immunosuppressive TME into an immunostimulatory TME via a higher but safe FUS dosage.

SUBMITTER: Chen KT 

PROVIDER: S-EPMC7864566 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors.

Chen Ko-Ting KT   Chai Wen-Yen WY   Lin Ya-Jui YJ   Lin Chia-Jung CJ   Chen Pin-Yuan PY   Tsai Hong-Chieh HC   Huang Chiung-Yin CY   Kuo John S JS   Liu Hao-Li HL   Wei Kuo-Chen KC  

Science advances 20210205 6


Focused ultrasound (FUS) in the presence of microbubbles can transiently open the blood-brain barrier (BBB) to increase therapeutic agent penetration at the targeted brain site to benefit recurrent glioblastoma (rGBM) treatment. This study is a dose-escalating pilot trial using a device combining neuronavigation and a manually operated frameless FUS system to treat rGBM patients. The safety and feasibility were established, while a dose-dependent BBB-opening effect was observed, which reverted t  ...[more]

Similar Datasets

| S-EPMC7966321 | biostudies-literature
| S-EPMC6693666 | biostudies-literature
| S-EPMC6060168 | biostudies-literature
| S-EPMC5881390 | biostudies-other
2023-06-17 | GSE198707 | GEO
| S-EPMC4614673 | biostudies-literature
| S-EPMC7859400 | biostudies-literature